MASI
Masimo Corp

1,802
Loading...
Loading...
News
all
press releases
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·8h ago
News Placeholder
More News
News Placeholder
Is the Options Market Predicting a Spike in Masimo Stock?
Investors need to pay close attention to MASI stock based on the movements in the options market lately.
Zacks·9h ago
News Placeholder
ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
Zacks·9h ago
News Placeholder
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
Zacks·9h ago
News Placeholder
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests
Hologic's shares rise after receiving FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform.
Zacks·9h ago
News Placeholder
IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.
Zacks·4d ago
News Placeholder
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
Zacks·4d ago
News Placeholder
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
Zacks·7d ago
News Placeholder
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Zacks·7d ago
News Placeholder
Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI
Two medical sector stocks are standing out among the recent additions to the Zacks Rank #1 (Strong Buy) list in Collegium Pharmaceutical (COLL) and Masimo Corporation (MASI).
Zacks·8d ago

Latest MASI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.